Geron (NASDAQ:GERN) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued on Wednesday.
A number of other research analysts have also recently issued reports on GERN. ValuEngine cut shares of Geron from a “buy” rating to a “hold” rating in a research note on Friday, May 11th. Stifel Nicolaus lifted their target price on shares of Geron from $2.50 to $4.00 and gave the company a “hold” rating in a research note on Sunday, March 18th. Zacks Investment Research upgraded shares of Geron from a “hold” rating to a “buy” rating and set a $4.50 target price for the company in a research note on Tuesday, April 24th. Finally, Piper Jaffray reiterated a “buy” rating and issued a $7.00 target price on shares of Geron in a research note on Monday, March 19th. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company’s stock. Geron has a consensus rating of “Hold” and an average price target of $5.17.
Geron opened at $3.38 on Wednesday, according to MarketBeat Ratings. Geron has a 1-year low of $3.31 and a 1-year high of $3.44.
Geron (NASDAQ:GERN) last released its quarterly earnings data on Thursday, May 10th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01. Geron had a negative return on equity of 26.20% and a negative net margin of 3,300.12%. The company had revenue of $0.32 million for the quarter. During the same period in the previous year, the firm posted ($0.05) earnings per share. sell-side analysts predict that Geron will post 0.19 earnings per share for the current year.
Large investors have recently bought and sold shares of the company. DekaBank Deutsche Girozentrale bought a new position in Geron in the 1st quarter worth approximately $106,000. Element Capital Management LLC bought a new position in Geron in the 1st quarter worth approximately $227,000. Bayesian Capital Management LP bought a new position in Geron in the 1st quarter worth approximately $250,000. Ladenburg Thalmann Financial Services Inc. raised its position in Geron by 57.5% in the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 70,970 shares of the biopharmaceutical company’s stock worth $302,000 after purchasing an additional 25,900 shares during the last quarter. Finally, MetLife Investment Advisors LLC bought a new position in Geron in the 4th quarter worth approximately $136,000. Institutional investors own 36.67% of the company’s stock.
Geron Corporation operates as a biopharmaceutical company. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses.
Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.